Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25339651 | 0.83 | LMNA (0.34) | — | |
| SCHEMBL15931182 | 0.82 | GAA (0.34) | — | |
| SCHEMBL15835018 | 0.80 | GAA (0.35) | — | |
| SCHEMBL9078126 | 0.80 | TSHR (0.30) | — | |
| SCHEMBL25277676 | 0.79 | CYP1A2 (0.30) | — | |
| SCHEMBL15933653 | 0.77 | — | — | |
| SCHEMBL19169898 | 0.76 | KMT2A (0.32) | — | |
| SCHEMBL15933562 | 0.74 | EPHX1 (0.36) | EPHX1 | |
| SCHEMBL25339543 | 0.73 | ALDH1A1 (0.34) | EPHX1 | |
| SCHEMBL25227444 | 0.73 | SMN1; SMN2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685737-B2 | Fluorinated integrin antagonists | OCUTERRA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20180016276-A1 | FLUORINATED 3-(2-OXO-3-(3-ARYLPROPYL)IMIDAZOLIDIN-1-YL)-3-ARYLPROPANOIC ACID DERIVATIVES | FELIQS CORPORATION (JP) | 2018-01-18 | — | — | US | disclosed |
| US-9802933-B2 | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802933-B2 | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170291900-A1 | FLUORINATED INTEGRIN ANTAGONISTS | FELIQS CORPORATION (JP) | 2017-10-12 | — | — | US | disclosed |
| US-20170291900-A1 | FLUORINATED INTEGRIN ANTAGONISTS | FELIQS CORPORATION (JP) | 2017-10-12 | — | — | US | disclosed |
| EP-2953948-B1 | FLUORINATED INTEGRIN ANTAGONISTS | SCIFLUOR LIFE SCIENCES INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9717729-B2 | Fluorinated integrin antagonists | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717729-B2 | Fluorinated integrin antagonists | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170096427-A1 | FLUORINATED 3-(2-OXO-3-(3-ARYLPROPYL)IMIDAZOLIDIN-1-YL)-3-ARYLPROPANOIC ACID DERIVATIVES | FELIQS CORPORATION (JP) | 2017-04-06 | — | — | US | disclosed |
| US-20160075698-A1 | FLUORINATED INTEGRIN ANTAGONISTS | FELIQS CORPORATION (JP) | 2016-03-17 | — | — | US | disclosed |
| US-9266884-B2 | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-y1)-3-arylpropanoic acid derivatives | SCIFLUOR LIFE SCIENCES, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266884-B2 | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-y1)-3-arylpropanoic acid derivatives | SCIFLUOR LIFE SCIENCES, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150057308-A1 | Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives | FELIQS CORPORATION (JP) | 2015-02-26 | — | — | US | disclosed |
| US-20150057308-A1 | Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives | FELIQS CORPORATION (JP) | 2015-02-26 | — | — | US | disclosed |
| US-8901144-B2 | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives | SCIFLUOR LIFE SCIENCES, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901144-B2 | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives | SCIFLUOR LIFE SCIENCES, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2014124302-A1 | FLUORINATED INTEGRIN ANTAGONISTS | SCIFLUOR LIFE SCIENCES, LLC (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140221410-A1 | Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives | SCIFLUOR LIFE SCIENCES, LLC (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221410-A1 | Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives | SCIFLUOR LIFE SCIENCES, LLC (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685737-B2 | Fluorinated integrin antagonists | ITGB5, ITGB1, ITGA5 | EPHX1 660/4885 |
| US-20150057308-A1 | Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives | ITGB3, ITGA2, ITGA1 | EPHX1 1967/4885 |
| US-20180016276-A1 | FLUORINATED 3-(2-OXO-3-(3-ARYLPROPYL)IMIDAZOLIDIN-1-YL)-3-ARYLPROPANOIC ACID DERIVATIVES | ITGB3, ITGA2, ITGA1 | EPHX1 1967/4885 |
| US-20140221410-A1 | Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives | ITGB3, ITGA2, ITGA1 | EPHX1 1967/4885 |
| US-20170096427-A1 | FLUORINATED 3-(2-OXO-3-(3-ARYLPROPYL)IMIDAZOLIDIN-1-YL)-3-ARYLPROPANOIC ACID DERIVATIVES | ITGB3, ITGA2, ITGA1 | EPHX1 1967/4885 |
| US-20160075698-A1 | FLUORINATED INTEGRIN ANTAGONISTS | ITGB5, ITGB1, ITGA5 | EPHX1 660/4885 |
| US-20170291900-A1 | FLUORINATED INTEGRIN ANTAGONISTS | ITGB5, ITGB1, ITGA5 | EPHX1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.